63 results
8-K
EX-99.2
PSTX
Poseida Therapeutics Inc
17 Apr 24
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
9:17am
Symptoms * 250 Per-patient Analysis Longitudinal assessment 221 patients with HAE 100% 97% 200 5736 patient-years of observation 150 131,110 … from novel tools to Accessibility help assessment of HAE control or normalization of life (89%) 22 Maurer M, et al. J Allergy Clin Immunol. 2021 May 25
8-K
EX-99.2
PSTX
Poseida Therapeutics Inc
11 Dec 23
Regulation FD Disclosure
6:06am
editing in resting T cells eliminates response assessment purple) at Week 6 (Day 44) post-infusion. Top row CD4+ SCM P = 0.0096 7 P = 0.0159 106 25 … for response assessment ITR CARGO ITR Peripheral blood samples of patient demonstrate P-BCMA-ALLO1 Figure 5—Data cutoff: October 23rd, 2023. ORR Objective
8-K
EX-99.2
t7reaq4fj go
6 Dec 22
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
6:06am
8-K
EX-1.1
s6pjpz
4 Aug 22
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
4:57pm
DEFA14A
x38t640qr
25 May 22
Additional proxy soliciting materials
5:18pm
8-K
zu72y2d4ukhpiqkm0p4t
18 May 22
Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors
8:05am
8-K
EX-99.1
0u8glajtlstl 3y7esp
23 Feb 22
Regulation FD Disclosure
6:08am